Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Ocular Therapeutix Inc (OCUL)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Ocular Therapeutix Inc's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.06 -0.21    -6.55%
10:50:21 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
ISIN:  US67576A1007 
CUSIP:  67576A100
  • Volume: 80,903
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 3.07 - 3.23
Ocular Therapeutix Inc 3.06 -0.21 -6.55%
Ocular Therapeutix Tops Q1 EPS by 4c
Ocular Therapeutix Tops Q1 EPS by 4c By Investing.com - May 09, 2022

Ocular Therapeutix (NASDAQ:OCUL) reported Q1 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $14.2...

Ocular Therapeutix Stock Tumbles After Eye Study Failure
Ocular Therapeutix Stock Tumbles After Eye Study Failure By Investing.com - Oct 22, 2021

By Sam Boughedda  Investing.com — Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) tumbled over 34% Friday after the failure of its Phase 2 clinical trial of OTX-CSI to treat dry eye disease. Ocular...

Ocular Therapeutix beats by $0.08, misses on revenue
Ocular Therapeutix beats by $0.08, misses on revenue By Seeking Alpha - Mar 08, 2018

Ocular Therapeutix (NASDAQ:OCUL): Q4 EPS of -$0.44 beats by $0.08.Revenue of $0.49M (-3.9% Y/Y) misses by $0.03M.Press ReleaseNow read: Your Daily Pharma Scoop: Conatus Rallies, Ionis Data, Reata's...

Premarket Losers as of 9:05 am (1/25/2018)
Premarket Losers as of 9:05 am (1/25/2018) By Seeking Alpha - Jan 25, 2018

CFMS -33% on pricing stock offering at $1.50.OCUL -12% on announcing public offering of common stock.ACHV -8%.VUZI -8% on announcing registered direct offering.NWL -7% on announcing preliminary 2017...

Healthcare Gainers / Losers as of 11:00 am
Healthcare Gainers / Losers as of 11:00 am By Seeking Alpha - Nov 27, 2017

Gainers: AHPI +26%. MGCD +24%. CERC +21%. FCSC +16%. NEPT +9%.Losers: RIOT -22%. QDEL -14%. GNCA -9%. OCUL -9%. ACST -9%.Now read: Trillium Therapeutics (TRIL) Presents At Society For Neuro Oncology...

Premarket Gainers as of 9:05 am
Premarket Gainers as of 9:05 am By Seeking Alpha - Jul 26, 2017

TTPH +23% on positive late-stage data on antibiotic eravacycline.IRBT +18% on Q2 result.ETRM +18%.AMD +8% on Q2 result.X +7% on Q2 result.OCUL +7% on positive analyst action.HMNY +6% on the launch of...

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

OCUL Comments

Write your thoughts about Ocular Therapeutix Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Scott Ornelas
Jatslo Oct 22, 2021 2:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
OCUL (P) 0.00000000 11.25000000
Roman Matějíček
Roman Matějíček Dec 02, 2020 11:38AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Wow!
Roman Matějíček
Roman Matějíček Mar 05, 2020 9:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Target?
Lindsay Marcus
Lindsay Apr 24, 2019 8:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Making a come back. Eye Think so!
Jeff Bailey
JeffB Nov 30, 2018 11:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$6.76 ... nice volume on extended move above 200-day SMA .... market participants must see an approval coming.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email